A phase II, multi-centre study to evaluate the safety and efficacy of tetradecanoylphorbol acetate in patients with acute myelocytic leukemia and myelodysplastic syndrome

Trial Profile

A phase II, multi-centre study to evaluate the safety and efficacy of tetradecanoylphorbol acetate in patients with acute myelocytic leukemia and myelodysplastic syndrome

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Tetradecanoylphorbol acetate (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 May 2017 According to a Rich Pharmaceuticals media release, the company has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok.
    • 31 May 2017 According to a Rich Pharmaceuticals media release, the company is preparing submission packages for the Hospital's Internal Review Board (IRB) and the Thailand Food and Drug Administration (FDA). This package is near completion and the Company plans to submit it shortly.
    • 16 Feb 2016 According to Rich Pharmaceuticals media release, company is planning to enrol patients from the US and Thailand.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top